Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus carboplatin and taxane versus carboplatin plus nab-paclitaxel in first-line stage IV squamous non-small cell lung cancer
NL-OMON47153Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, carboplatin and paclitaxel in Pulmonary squamous cell carcinoma (3 arms), sponsored by Roche. Primary endpoints: Progression-free survival and Overall survival. Started Jan 2016; status: active, not recruiting.
02
Drugs
atezolizumabcarboplatinpaclitaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON47153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47153.